What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE: LLY) jumped 4.3% in the morning session after the stock continued to rally as the company reported strong first-quarter 2026 financial results that surpassed analyst expectations and raised its full-year guidance.
The pharmaceutical giant announced that its first-quarter revenue grew 56% to $19.8 billion, significantly beating analyst forecasts. This growth was driven by soaring demand for its popular GLP-1 drugs, Mounjaro and Zepbound, which generated a combined $12.8 billion in sales. The strong performance led to a 156% increase in non-GAAP earnings per share.
Citing this momentum, Eli Lilly raised its full-year revenue forecast to a range of $82 billion to $85 billion and boosted its earnings guidance. Adding to the positive sentiment, the FDA proposed a rule that would prohibit compounding facilities from making copycat versions of the company's key drugs, further protecting its market.
After the initial pop the shares cooled down to $963.54, up 3.1% from previous close.
Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Eli Lilly’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 7 days ago when the stock dropped 3.6% on the news that disappointing weekly prescription numbers for its key weight-loss drugs sparked concerns about its competitive standing against rival Novo Nordisk.
Data for the week ending April 17 showed that prescriptions for Lilly's injectable weight-loss drug, Zepbound, decreased, while its competitor's drug, Wegovy, saw an increase. More concerning for investors were the early numbers for Lilly's newly launched oral obesity pill, Foundayo. In its second week, it secured 3,707 prescriptions, which significantly trailed the 18,410 prescriptions Novo Nordisk's rival pill achieved in its second week.
Eli Lilly is down 10.8% since the beginning of the year, and at $963.54 per share, it is trading 13.2% below its 52-week high of $1,110 from November 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $5,183.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
